TREM2 Limits Progression of Deficits and Spreading of Tau Pathology in Mice

Background. Amyloid-β (Aβ) and tau form pathogenic lesions in Alzheimer’s disease (AD) brains. As ΑD clinically progresses, tau pathology propagates in a very distinct pattern between connected brain areas. The molecular mechanisms underlying this tau pathology spread remain largely unknown. Genome-wide association studies have identified polymorphisms in triggering receptor expressed on myeloid cells 2 ( TREM2 ) as genetic risk factors for AD and regulators of Aβ pathology-dependent tau propagation. Whether TREM2 contributes to neuron-to-neuron spreading of pathological tau remains unknown.Methods. Here, we crossed Trem2- deficient mice with P301S tau transgenic TAU58 mice and subjected the mice to behavioral testing and assessed neuropathology. Microglial activation states were determined using cytometry by of flight (CyTOF) and quantitative PCR. Tau spreading was assessed in vivo using tracing of focal tau expression.Results. Trem2 depletion significantly aggravated tau-induced early-onset motor and behavioural deficits. Neuropathologically, Trem2 reduction increased the number of hyperphosphorylated tau lesions in young TAU58 brains and reduced disease-associated microglia. Direct assessment of inter-neuronal spread of tau in vivo revealed significantly enhanced propagation of tau in the absence of Trem2 , suggesting that microglial TREM2 limits the progression of tau pathology in disease.Conclusion. Taken together, our data suggests that reduced TREM2 function accelerates the onset and progression of functional deficits and tau neuropathology in tau transgenic mice, which is - at least in part - due to increased tau spreading. Therefore, reduced TREM2 function may contribute to early AD by augmenting tau toxicity and its inter-neuronal propagation.

[1]  Melanie A. Huntley,et al.  Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology , 2021, Neuron.

[2]  A. Ittner,et al.  Novel Behavioural Characteristics of Male Human P301S Mutant Tau Transgenic Mice – A Model for Tauopathy , 2020, Neuroscience.

[3]  B. Hyman,et al.  Experimental evidence for the age dependence of tau protein spread in the brain , 2019, Science Advances.

[4]  Virginia M. Y. Lee,et al.  TREM2 function impedes tau seeding in neuritic plaques , 2019, Nature Neuroscience.

[5]  Bin Zhang,et al.  Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau , 2018, Molecular Psychiatry.

[6]  G. Coppola,et al.  Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy , 2018, Proceedings of the National Academy of Sciences.

[7]  Derek H. Oakley,et al.  The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer’s disease , 2018, Journal of Neuroinflammation.

[8]  B. Becher,et al.  Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Medicine.

[9]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[10]  T. Fath,et al.  Tau exacerbates excitotoxic brain damage in an animal model of stroke , 2017, Nature Communications.

[11]  Matthew P Frosch,et al.  Enhanced Tau Aggregation in the Presence of Amyloid β. , 2017, The American journal of pathology.

[12]  L. Ittner,et al.  Generation of Genetically Modified Mice through the Microinjection of Oocytes. , 2017, Journal of visualized experiments : JoVE.

[13]  David V. Hansen,et al.  TREM2, Microglia, and Neurodegenerative Diseases. , 2017, Trends in molecular medicine.

[14]  B. Becher,et al.  CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets , 2017, F1000Research.

[15]  W. Wurst,et al.  TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury , 2017, EMBO reports.

[16]  Huaxi Xu,et al.  TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway , 2017, The Journal of Neuroscience.

[17]  Yves Dauvilliers,et al.  High-dimensional single-cell analysis reveals the immune signature of narcolepsy , 2016, The Journal of experimental medicine.

[18]  A. Bongers,et al.  No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice , 2016, PloS one.

[19]  J. Hodges,et al.  Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia , 2016, Neuroscience Letters.

[20]  Lino C. Gonzalez,et al.  TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia , 2016, Neuron.

[21]  L. Tan,et al.  TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice , 2016, Neuropharmacology.

[22]  D. Holtzman,et al.  TREM2 Function in Alzheimer's Disease and Neurodegeneration. , 2016, ACS chemical neuroscience.

[23]  B. Hyman,et al.  Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity , 2015, The EMBO journal.

[24]  J. Hodges,et al.  Early‐onset axonal pathology in a novel P301S‐Tau transgenic mouse model of frontotemporal lobar degeneration , 2015, Neuropathology and applied neurobiology.

[25]  L. Tan,et al.  Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice , 2015, Neurobiology of Aging.

[26]  D. Rujescu,et al.  The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease , 2015, Alzheimer's & Dementia.

[27]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[28]  G. Halliday,et al.  Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS , 2015, Acta Neuropathologica.

[29]  S. Younkin,et al.  Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)* , 2015, The Journal of Biological Chemistry.

[30]  S. Paul,et al.  Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody , 2015, Scientific Reports.

[31]  Guixiang Xu,et al.  Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. , 2015, Brain : a journal of neurology.

[32]  M. Colonna,et al.  TREM2 sustains microglial expansion during aging and response to demyelination. , 2015, The Journal of clinical investigation.

[33]  H. Maecker,et al.  Barcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry , 2015, The Journal of Immunology.

[34]  L. Tan,et al.  Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[35]  Teng Jiang,et al.  Microglia in Alzheimer's Disease , 2014, BioMed research international.

[36]  J. Molinuevo,et al.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis , 2014, Science Translational Medicine.

[37]  D. Holtzman,et al.  Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 , 2014, Molecular Neurodegeneration.

[38]  A. Pestronk,et al.  TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. , 2014, JAMA neurology.

[39]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[40]  M. Prinz,et al.  Factors regulating microglia activation , 2013, Front. Cell. Neurosci..

[41]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[42]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[43]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[44]  J. Hodges,et al.  Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains , 2009, Journal of Neural Transmission.

[45]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[46]  J. Götz,et al.  Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.

[47]  Jürgen Götz,et al.  A Decade of Tau Transgenic Animal Models and Beyond , 2007, Brain pathology.

[48]  H. Neumann,et al.  Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2 , 2005, The Journal of experimental medicine.

[49]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[50]  H. Brodaty,et al.  ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.

[51]  A. Larner,et al.  Behavioral Variant Frontotemporal Dementia-like Syndrome With Novel Heterozygous TREM2 Frameshift Mutation. , 2019, Alzheimer disease and associated disorders.

[52]  A. Naganuma,et al.  Evaluation of M1-microglial activation by neurotoxic metals using optimized organotypic cerebral slice cultures. , 2019, The Journal of toxicological sciences.

[53]  T. Tomita,et al.  Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. , 2019, Advances in experimental medicine and biology.

[54]  V. Redaelli,et al.  Frontotemporal Dementia and Chorea Associated with a Compound Heterozygous TREM2 Mutation. , 2018, Journal of Alzheimer's disease : JAD.

[55]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.